Compare CTNM & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CTNM | IGR |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.7M | 546.3M |
| IPO Year | 2024 | 2003 |
| Metric | CTNM | IGR |
|---|---|---|
| Price | $8.95 | $10.82 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $22.14 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 501.5K |
| Earning Date | 11-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.73 | $4.15 |
| 52 Week High | $17.79 | $13.67 |
| Indicator | CTNM | IGR |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 50.31 |
| Support Level | $6.73 | $4.54 |
| Resistance Level | $13.72 | $13.67 |
| Average True Range (ATR) | 1.00 | 0.24 |
| MACD | 0.06 | -0.19 |
| Stochastic Oscillator | 32.33 | 28.09 |
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.